Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus

Naturally pyrazinamide (PZA)–resistant Mycobacterium bovis and acquired PZA–resistant M. tuberculosis strains lose pyrazinamidase (PZase). To investigate the molecular mechanism of PZA resistance, we have cloned the gene (pncA) encoding M. tuberculosis PZase. Mutations in pncA were identified in both types of PZA–resistant strains, and transformation of these strains with a functional pncA gene restored PZase activity and PZA susceptibility. These findings, besides providing the basis for understanding how PZA works, should have implications for rapid detection of PZA–resistant clinical isolates of M. tuberculosis and also for rapid differentiation of M. bovis from M. tuberculosis strains.

[1]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[2]  L. Heifets,et al.  Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. , 1992, The American review of respiratory disease.

[3]  Tarshis Ms,et al.  Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. , 1953 .

[4]  W. Mcdermott,et al.  THE FATE OF MYCOBACTERIUM TUBERCULOSIS IN MOUSE TISSUES AS DETERMINED BY THE MICROBIAL ENUMERATION TECHNIQUE , 1956, The Journal of experimental medicine.

[5]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[6]  M. Cynamon,et al.  Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility , 1996, Antimicrobial agents and chemotherapy.

[7]  D. Young,et al.  Transformation of mycobacterial species using hygromycin resistance as selectable marker. , 1994, Microbiology.

[8]  Christopher J. L. Murray,et al.  Tuberculosis: Commentary on a Reemergent Killer , 1992, Science.

[9]  D. Snider,et al.  Nationwide survey of drug-resistant tuberculosis in the United States. , 1994, JAMA.

[10]  I. Beacham,et al.  Structure and expression in Escherichia coli K-12 of the L-asparaginase I-encoding ansA gene and its flanking regions. , 1989, Gene.

[11]  E. Böttger,et al.  Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot , 1993, Molecular microbiology.

[12]  D. Mitchison,et al.  Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. , 1970, Tubercle.

[13]  D. Mitchison.  The action of antituberculosis drugs in short-course chemotherapy. , 1985, Tubercle.

[14]  D. Young,et al.  Transformation with katG restores isoniazid‐sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations , 1993, Molecular microbiology.

[15]  Mackaness Gb.  The intracellular activation of pyrazinamide and nicotinamide. , 1956 .

[16]  J. Foster,et al.  Pyridine nucleotide cycle of Salmonella typhimurium: isolation and characterization of pncA, pncB, and pncC mutants and utilization of exogenous nicotinamide adenine dinucleotide , 1979, Journal of bacteriology.

[17]  M. Patarroyo,et al.  Species-specific identification of Mycobacterium bovis by PCR. , 1995, Microbiology.

[18]  K. Mullis,et al.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. , 1988, Science.

[19]  S. Cole,et al.  The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis , 1992, Nature.

[20]  S. Trivedi,et al.  Pyrazinamidase activity of Mycobacterium tuberculosis--a test of sensitivity to pyrazinamide. , 1987, Tubercle.

[21]  L. Wayne,et al.  Simple pyrazinamidase and urease tests for routine identification of mycobacteria. , 1974, The American review of respiratory disease.

[22]  A. Telenti,et al.  Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis , 1993, The Lancet.

[23]  R. Yeager,et al.  Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. , 1952, American review of tuberculosis.

[24]  R. Lathigra,et al.  Alterations in the superoxide dismutase gene of an isoniazid-resistant strain of Mycobacterium tuberculosis , 1992, Infection and immunity.

[25]  P. S. Skinner,et al.  A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions , 1994, Antimicrobial Agents and Chemotherapy.

[26]  A. Tsang,et al.  Use of pyrazinamidase activity on Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility , 1981, Antimicrobial Agents and Chemotherapy.

[27]  W. Mcdermott,et al.  Pyrazinamide susceptibility and amidase activity of tubercle bacilli. , 1967, The American review of respiratory disease.

[28]  W. Jacobs,et al.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.

[29]  R. Dahl,et al.  Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic , 1991, Infection and immunity.